COMUNICADO: Un estudio demuestra que DIFICLIR[TM] ofrece beneficios potenciales (y 2)

[TAB]

1) Cornely A, et al. Fidaxomicin versus vancomycin for infection with

Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority,

randomised controlled trial. Lancet Infect Diseases. doi: 10.1016/S1473-3099(11

)70374-7.

2) European Centre for Disease Prevention and Control.

http://ecdc.europa.eu/en/healthtopics/healthcare-associated_infections/pages/index.aspx

. Ultimo acceso enero de 2011.

3) Simor AE, et al. Clostridium difficile in long-term-care facilities for the

elderly. Infect Control Hosp Epidemiol. 2002; 23:696-703.

4) Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk

factors and management. Nat Rev Gastroenterol Hepatol. 2011; 8:17-26.

5) Bouza E, et al. Results of a phase III trial comparing tolevamer, vancomycin

and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin

Micro Infect. 2008; 14(Suppl 7):S103-4.

6) Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium

difficile Toxins. N Engl J Med. 2010; 362; 3:197-205.

7) Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile

infection. N Engl J Med. 2011; 364:422-31.

8) Bauer MP, et al. European Society of Clinical Microbiology and Infectious

Disease (ESCMID): treatment guidance document for Clostridium difficile-infection

(CDI). Clin Microbiol Infect. 2009; 15:1067-79.

9) Food and Drug Administration. FDA approves treatment for Clostridium

difficile infection [Internet]. [actualizado 27 de mayo de 2011; citado el 16 de

septiembre de 2011]. Disponible desde

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm.

10) European Commission. Community register of medicinal products for human use.

http://ec.europa.eu/health/documents/community-register/html/h733.htm. Ultimo

acceso marzo de 2012.

11) McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic

findings and advances in therapy. Pharmacotherapy. 2007; 27:1029-39.

12) Pepin J, et al. Increasing risk of relapse after treatment of Clostridium

difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40:1591-7.

13) Ghantoji SS, et al. Economic healthcare costs of Clostridium difficile

infection: a systematic review. J Hosp Infect. 2010; 74:309-18.

14) Kyne L, et al. Health care costs and mortality associated with nosocomial

diarrhea due to Clostridium difficile. Clin Infect Dis. 2002; 1; 34(3):346-53.

[FTAB]

CONTACTO: Si desea más información contacte con: Katy Compton-Bishop,Ruder Finn, kcompton-bishop@ruderfinn.co.uk, Tel: +44(0)207-438-3069; MindyDooa, Astellas Pharma Europe Ltd, mindy.dooa@eu.astellas.com, Tel:+44(0)1784-419-444

WhatsAppFacebookTwitterLinkedinBeloudBluesky